INTRODUCTION
The discovery of regulatory RNAs has revolutionized the traditional concept of RNA function and gene regulation (Zamore and Haley, 2005) . The hunt for novel RNA species is gaining momentum, and natural antisense transcripts potentially constitute a large class of regulatory RNAs. This is supported by sequencing data showing that 20% of all human genes overlap (Chen et al., 2004; Yelin et al., 2003) . However, the functional relevance of antisense transcription as well as the cellular mechanism(s) involved remains largely speculative for the large majority of bidirectionally transcribed genes. Only a few studies actually describe their biological role, such as the antisense transcripts Air and Xist in mice (Lee and Lu, 1999; Sleutels et al., 2002 ). These reports demonstrate that knockout of the antisense transcript causes aberrant expression of the sense transcript with a related phenotype. Recent studies indicate that antisense transcription occurs in up to 70% of all mammalian genes (Katayama et al., 2005) , suggesting a pivotal role of antisense transcripts in eukaryotic gene expression. Therefore, it is of great interest to demonstrate the functional role of antisense transcripts in humans.
The tumor suppressor gene p53 is a transcription factor that protects the organism from potentially harmful cells carrying damaged DNA or activated oncogenes by inducing their growth arrest or apoptosis (Vousden and Lu, 2002) . To evade this response cancer cells often inactivate p53, thus making p53 the most frequently mutated gene in human cancer (http:// www-p53.iarc.fr/; http://p53.free.fr; Olivier et al., 2002) . DNA damage and other stress conditions trigger a significant increase in p53 protein half life and also activate p53 as a transcription factor. Therefore, most studies of p53 regulation have focused on the p53 protein, whereas regulation at the RNA level has received less attention. Takagi et al. (2005) demonstrated that translational regulation contributes to p53 induction after DNA damage by the binding of specific proteins to the p53 5 0 untranslated region (UTR). This indicates a critical role of p53 mRNA availability for p53 induction upon cellular stress. Posttranscriptional control of p53 has also been reported, but the responsible mechanisms have not been elucidated. Levels of p53 RNA were shown to decrease during proliferation, differentiation (Dony et al., 1985; Klinken et al., 1988) , and immortalization (Kim et al., 2001a (Kim et al., , 2001b . These changes could not be coupled to de novo synthesis of p53 mRNA, since the transcription rate was fairly constant between the different cell states. Instead, p53 mRNA was thought to be regulated at the posttranscriptional level. In mouse cells, a similar posttrancriptional regulation of p53 was observed upon induction of differentiation, affecting p53 pre-mRNA maturation and possibly involving an antisense RNA transcript (Khochbin et al., 1992; Khochbin and Lawrence, 1989) . However, the exact molecular mechanisms remained unclear. Here, we report the identification and characterization of a highly conserved natural antisense transcript to p53, Wrap53, that has a critical role in the regulation of p53 at the RNA level.
RESULTS

Wrap53-A Natural p53 Antisense Transcript
Analysis of the GenBank EST database indicated that a novel gene is located immediately upstream of the p53 gene on the opposite strand ( Figure 1A ). We cloned this gene and found that it is alternatively spliced (at least 17 variants, Figure S1 available online) and has three alternative start exons: exon 1a, 1b, and 1g ( Figure 1B) . Interestingly, exon 1a directly overlaps the first exon of p53 in an antisense fashion by up to 227 base pairs (bp), depending on transcription start site (TSS) usage (Tuck and Crawford, 1989) (Figure 1B) . The finding of a p53 antisense transcript evoked our interest, since antisense transcripts have previously been suggested to regulate their overlapping sense transcripts (Katayama et al., 2005) . We termed this gene Wrap53 for WD40-encoding RNA antisense to p53. Exon 1g of Wrap53 is located in the first intron of p53 overlapping the previously identified transcript Hp53int1 (Reisman et al., 1996) in an antisense fashion ( Figure 1B ). Exon 1b is located downstream of exon 1a, and initiation from this start exon will produce transcripts lacking complementarity to p53 mRNAs. Transcripts initiated from exon 1a, 1b, and 1g will herein be called Wrap53a, Wrap53b, and Wrap53g transcripts, respectively. Wrap53 also encodes a WD40 domain protein homologous to members of the large WD40 family of proteins with diverse functions. However, the function of the Wrap53 protein is unknown, and the present study is focused on the role of Wrap53a as an antisense RNA that regulates p53. Interestingly, we found that the p53 family gene p73 also has an overlapping antisense gene, albeit one that overlaps with respect to intron rather than exonic sequences. This p73 antisense transcript was cloned and Figure 1A and Figure S2 ). We did not identify an antisense gene for p63. Furthermore, we performed a comparative analysis of the p53-Wrap53 and p73-Wrap73/WDR8 genomic regions in eukaryotes. The close location of Wrap53/p53 and WDR8/p73 has been maintained throughout evolution, at least in mammals (Table S1 ), supporting our conclusion that this genomic arrangement has a biological function. The comparative analysis is further described in the Supplemental Data.
As a first step to determine if Wrap53 regulates p53, the expression of Wrap53 was analyzed in normal human tissues and cancer cell lines and compared to p53 expression. Wrap53 is expressed in all tissues and cell lines examined ( Figures S3A-S3C ). Analysis by QuantiGene (Canales et al., 2006) revealed that p53 mRNA is expressed at 100-fold higher levels than the Wrap53a transcript ( Figure S3C ), which is in agreement with other reports showing that antisense transcripts are usually expressed at lower levels compared to their corresponding sense transcript (Chen et al., 2005; Fish et al., 2007) . Interestingly, linear regression analysis showed a strong and positive correlation between p53 and Wrap53a expression (r 2 = 0.691, p = 0.081, n = 5) in the panel of cell lines analyzed ( Figure S3C ). Indeed, recent studies demonstrate that expression of most sense/antisense pairs is positively correlated (Chen et al., 2005; Katayama et al., 2005; Oeder et al., 2007) .
Wrap53 Regulates p53 mRNA and Protein
To investigate a possible regulation of p53 by the Wrap53 antisense transcript, we analyzed changes in p53 mRNA levels after silencing Wrap53 expression. Strikingly, knockdown of Wrap53 by siRNA (siWrap53-E9) in U2OS and HCT116 cells led to a significant decrease in p53 mRNA levels ( Figure 2A ). To confirm that knockdown of Wrap53 does not induce general downregulation of genes, p73 and b-Actin RNA levels were analyzed on the same filter and found to be unchanged. We also observed a significant reduction in p53 protein levels following knockdown of Wrap53 ( Figure 2B ). Furthermore, reduced levels of p53 following Wrap53 depletion were observed in MCF-7 cells (data not shown) and in human fibroblasts ( Figure S4A ), indicating that Wrap53 regulates p53 also in normal cells. Wrap53 also regulates the levels of mutant p53. Knockdown of Wrap53 in mutant p53-expressing C33A cells reduced mutant p53 mRNA levels by 30%-40% ( Figure S4B ). Thus, this finding raises the possibility of targeting Wrap53 as a therapeutic strategy for tumors harboring mutant p53. Several siRNAs targeting different common exons of Wrap53 (their position shown in Figure 2C ) all caused a reproducible decrease in p53 mRNA levels, although with variable efficiency ( Figure S4C ). We next designed transcript-specific siRNAs, specifically targeting exons 1a, 1b, and 1g of Wrap53. Northern blot analysis showed that only siWrap53a caused a reduction in p53 mRNA levels ( Figure 2D ). This was confirmed by QuantiGene analysis where RNA is quantified directly from crude cell lysates without any RNA purification, reverse transcription, or target amplification. According to our QuantiGene analysis, siWrap53a reduced p53 RNA levels by 83% ( Figure 2E ). In contrast, siWrap53b or siWrap53g did not downregulate p53. This indicates that exon 1a-containing transcripts are responsible for regulating p53. The specificity of the siWrap53a/b/g oligonucleotides was confirmed by quantitative RT-PCR ( Figure S5 ). Wrap53g transcripts are not expressed in HCT116 and MCF-7 cells, but these cell lines nonetheless show Wrap53-mediated p53 regulation, further supporting that Wrap53g transcripts are not involved.
The siWrap53a oligonucleotides were designed to target exon 1a sequences that do not overlap with p53, to avoid crosssilencing of the opposite strand. As shown in several studies, around 95% of p53 transcripts starting from exon 1 initiate from P1 (indicated in Figure 1B ) (Takagi et al., 2005; Tuck and Crawford, 1989) . We confirmed this by performing RT-PCR on total RNA extracted from U2OS cells with a forward primer located in p53 exon 4 (4F) and reverse primers located upstream (1aR) or downstream (1R) of P1 (data not shown). Consequently, the siWrap53a oligonucleotides should not cross-silence the majority of p53 transcripts. Importantly, the siWrap53a oligonucleotides only depleted Wrap53a RNA and did not affect Wrap53 protein levels, indicating that the majority of Wrap53 protein is encoded by other transcripts than Wrap53a.
The relationship between the sense and antisense transcripts was further examined by transiently overexpressing Wrap53. Different constructs were used, either generating full-length Wrap53 transcripts or only exon 1a or 1b of Wrap53. Interestingly, only overexpression of transcripts containing exon 1a (i.e., CMVWrap53-E1aS/L or CMV-Wrap53 aStop ) resulted in increased p53 RNA and protein levels, whereas constructs lacking this sequence (i.e., CMV-Wrap53-E1b or CMV-Wrap53
Da ) failed to affect p53 levels (Figures 3A and 3B and Figure S6 ). Quantification of p53 RNA showed that overexpression of exon 1a increases p53 levels 3-fold compared to empty vector or exon 1b ( Figure 3A ), supporting the idea that the antisense exon 1a is involved in the regulation of p53 mRNA. In addition, restoration of Wrap53a expression by transfection of a Wrap53a cDNA construct (CMV-Wrap53 aStop ) indeed rescued the downregulation of p53 upon Wrap53 knockdown ( Figure 3C ).
To investigate a possible reciprocal regulation, we examined Wrap53a mRNA levels upon silencing and overexpression of p53. We did not detect any changes in Wrap53a levels, indicating that Wrap53 regulates p53 in a nonreciprocal manner ( Figure S7 ).
Wrap53 mRNA Regulates p53 siRNA silencing of Wrap53 (siWrap53-E9) results in knockdown of both Wrap53 RNA and protein. Several observations demonstrated that that Wrap53 mRNA rather than the Wrap53 protein regulates p53 expression. First, p53 levels were largely unaffected by overexpression of full-length Wrap53 protein per se 
(CMV-Wrap53
Da construct in Figure S6 ). Second, overexpression of the overlapping exon 1a, which does not encode any protein, efficiently induced p53 levels ( Figures 3A and 3B) . Third, siWrap53a oligonucleotides that only target exon 1a-containing transcripts and, thus, do not inhibit expression of endogenous Wrap53 protein were nonetheless capable of downregulating p53 expression ( Figures 2D, 2E , and 3D). Fourth, restoration of Wrap53a expression by a Wrap53a cDNA construct only giving rise to a truncated Wrap53 protein indeed rescued the downregulation of p53 upon Wrap53 knockdown ( Figure 3C ). Fifth, reintroduction of full-length Wrap53 protein did not rescue p53 expression upon siWrap53 treatment (data not shown).
The finding that the antisense exon of Wrap53 (exon 1a) is critical for the effects on p53 pinpoints Wrap53 mRNA rather than the Wrap53 protein as a regulator of p53 expression.
We next examined if p53 regulation by Wrap53 occurs at the level of p53 transcription or at a posttranscriptional level. Using a luciferase construct containing the promoter region of human p53 (Reisman et al., 1988) (Figure S8A ), we examined the influence of Wrap53 depletion and overexpression on p53 promoter activity. No differences in luciferase activity were observed, indicating that Wrap53 regulates p53 at the posttranscriptional level and not at the level of p53 transcription ( Figure S8B ). In addition, we found that Wrap53 silencing only decreases p53 mRNA and not p53 pre-mRNA levels ( Figure S9 ). The fact that Wrap53 specifically regulates the mature form of p53 RNA further supports the notion that Wrap53 regulates p53 at the posttranscriptional level.
Crucial Role of the Antisense Region for Wrap53-Mediated Regulation of p53 Sense and antisense transcripts may potentially interact through their complementary regions, resulting in double-stranded RNA structures that regulate stability, transport, and/or translation of the sense transcript. To determine if this is the case for Wrap53 and p53, we generated luciferase reporter constructs carrying the Wrap53-complementary region of p53. A 227 bp fragment of p53 exon 1 (as counted from the 3 0 end of p53 exon 1), corresponding to the entire overlap between p53 and Wrap53, was inserted immediately upstream of the luciferase reporter gene in the pGL3 Promoter vector ( Figure 4A ). As control, a luciferase vector without upstream p53 sequences (Luc/empty) was used. Thus, any changes in luciferase activity between the two constructs should be due to effects mediated by p53 exon 1. Strikingly, the p53 exon 1 containing-construct showed a 86% reduction in luciferase activity in cells depleted for Wrap53, whereas the control construct was unaffected by Wrap53 depletion ( Figure 4B ). We also knocked down Wrap53a and Wrap53b transcripts separately, and only cells lacking Wrap53a transcripts showed a reduction in luciferase activity (75% reduction). The control construct was unaffected by all Wrap53 siRNAs, strongly supporting our hypothesis that the first exon of p53 is crucial for Wrap53-mediated regulation of p53.
A shorter construct was generated containing the most 3 0 120 bp of p53 exon 1 in front of the firefly luciferase gene (Luc/ p53-E1 Short), representing p53 transcription initiated from P1. We observed a 52%-66% reduction in luciferase activity upon knockdown of Wrap53 ( Figure 4B ). These experiments demonstrate that p53 mRNA is regulated by Wrap53 through sequences in exon 1 of p53 and that the length of p53 exon 1 is important for this effect. Conservation of genomic elements suggests functional importance. We, therefore, analyzed the genomic arrangement of p53 and Wrap53 with regard to its conservation during evolution. In general, 5 0 and 3 0 UTRs are much less conserved in comparison to translated exons. Interestingly, we found that the overlapping region of Wrap53 and p53 is highly conserved, with up to 91% sequence identity between human and mouse. Although this may in part be due to the presence of p53 promoter sequences (Tuck and Crawford, 1989) , the degree of conservation is remarkable and, in fact, even higher than that of many of the coding exons within the two genes. Moreover, p53 and Wrap53 ESTs with a 171 bp overlap in the first exons are also expressed in mouse cells (for GenBank accession numbers, see the Experimental Procedures). Thus, the antisense arrangement of p53 and Wrap53 is conserved between human and mouse, supporting the notion that it has a significant function and that Wrap53 regulates p53 through the antisense overlap.
Inhibition of Potential p53-Wrap53 RNA Interaction Reduces p53 Levels Our data demonstrate that the shared sequence of p53 and Wrap53 is involved in the regulation of p53 by Wrap53. To elucidate if RNA/RNA interaction mediates this regulation, we designed 2 0 -O-methyl oligoribonucleotides to inhibit potential Wrap53/p53 hybridization. Such oligoribonucleotides are small singlestranded RNA fragments that block microRNA and target-mRNA pairing (Hutvagner et al., 2004) . Transfection of either a Wrap53-specific (Wrap53-E1a-AS) or a p53-specific (p53-E1-AS) oligonucleotide that targets the shared mRNA sequence and, thus, prevents interaction between p53 and Wrap53 mRNAs led to a specific reduction of p53 expression, whereas the control-AS had no effect ( Figure 4C ). Thus, blocking potential Wrap53/p53 RNA duplexes reduces p53 levels in the same way as knockdown of Wrap53 by siRNA, suggesting that this RNA-RNA interaction is required to maintain normal levels of p53 in the cell. We next examined formation of RNA duplexes between the p53 and Wrap53 transcripts. Full-length p53 and Wrap53a were cotranscribed in vitro and analyzed by RNase protection assay (RPA). Single-stranded RNA was digested with RNase A, and remaining double-stranded RNA was analyzed by RT-PCR using primers corresponding to different regions of the two transcripts. Only primers within the overlapping region of p53 and Wrap53 generated a PCR product ( Figure S10 ). This demonstrates that the p53 sense and Wrap53a antisense transcripts are indeed capable of forming duplex RNA when coexpressed.
Wrap53 Regulates p53 Both in the Nucleus and in the Cytoplasm
We further investigated the cellular location of Wrap53-mediated p53 decay. By analyzing cytoplasmic and nuclear fractions separately, we observed that p53 RNA and protein were reduced both in the cytoplasm and the nucleus after siWrap53 treatment ( Figures 5A and 5B) . The loss of p53 in the cytoplasm could either be due to cytoplasmic p53 mRNA decay or a consequence of p53 decay in the nucleus. To further examine this, we used cytoplasts of U2OS cells in which nuclei have been removed by Cytochalasin B treatment. Since siRNA knockdown experiments were inefficient in cytoplasts, we used the p53-E1-AS oligoribonucleotides to inhibit Wrap53/p53 interaction. Cytoplasmic levels of p53 were reduced upon p53-E1-AS transfection ( Figure S11 ), demonstrating that decay of p53 does occur in the cytoplasm independent of the nucleus. This also suggests that p53 and Wrap53 RNA interact in the cytoplasm.
Wrap53a Is Required for p53 Induction upon DNA Damage
To explore the functional significance of Wrap53-mediated p53 regulation, we analyzed if the p53 response to DNA damage is affected by Wrap53 depletion. U2OS and HCT116 cells were pretreated with siWrap53-E9 or siWrap53a for 32 hr to reduce p53 mRNA before the addition of the DNA-damaging drugs camptothecin (CPT) or mitomycin C (MMC) for additional 16 hr. As shown in Figure 6A , p53 protein levels were induced upon CPT and MMC treatment in cells pretreated with siControl, followed by induction of the target genes p21 and PUMA. In contrast, cells pretreated with siWrap53-E9 or siWrap53a showed significantly lower levels of p53 protein after CPT and MMC treatment, and no induction of target genes could be detected. p53 RNA levels were also markedly reduced ( Figure 6B ). Interestingly, p53 mRNA levels were increased after both CPT and MMC treatment, suggesting that elevated p53 mRNA levels contributes to its induction upon DNA damage. This is consistent with recent studies showing that induction of p53 transcription and p53 mRNA availability contributes to p53 protein accumulation during stress conditions (Takagi et al., 2005; Wang and El-Deiry, 2006) . Knockdown of endogenous Wrap53 abrogates p53 induction upon DNA damage also in human fibroblasts ( Figure S4A ).
We also treated cells with Wrap53-E1a-AS or p53-E1-AS in combination with MMC. Similar to siWrap53-E9 and siWrap53a, both these oligoribonucleotides reduced p53 mRNA levels and prevented induction of p53 protein after DNA damage ( Figures  6C and 6D ). These results demonstrate that Wrap53 expression and interaction with p53 mRNA is necessary for proper induction of p53 upon DNA damage by maintaining sufficient levels of p53 RNA.
Furthermore, we quantified p53 and Wrap53 RNA levels at different time points of MMC treatment. Both p53 and Wrap53a transcripts were induced upon MMC treatment, in contrast to the Wrap53b and g transcripts that were reduced by MMC ( Figure 6E and Figure S12 ). This suggests that Wrap53a not only maintains basal p53 mRNA levels but also plays a role in stabilizing p53 mRNA in response to DNA damage.
Overexpression of Wrap53a Potentiates p53-Induced Apoptosis
Our finding that Wrap53 regulates p53 mRNA expression prompted us to investigate its impact on p53-induced apoptosis. MCF-7 cells carrying wild-type p53 were transfected with either empty vector or CMV-Wrap53 aStop expression vector and thereafter treated with MMC. Apoptosis was assessed by TMRE and Annexin V staining followed by FACS analysis. MMC treatment led to disruption of mitochondrial membrane potential in 82% in CMV-Wrap53 aStop transfected cells compared to 57% of mocktransfected cells ( Figure 7A ). Thus, ectopic expression of Wrap53a mRNA caused a substantial increase (44%) in MMCinduced apoptosis. Annexin V staining confirmed a significant increase (29%) in MMC induced following Wrap53a mRNA overexpression ( Figure 7B ). We performed the same experiments in MCF-7 p53kd cells that lack wild-type p53 expression due to stable shRNA knockdown of p53 ( Figure 7C ). No change in TMRE nor Annexin V staining was observed after CMV-Wrap53 aStop transfection ( Figures 7A and 7B) , verifying that Wrap53a regulates p53-dependent apoptosis. We conclude that Wrap53 has a significant impact on p53 and the p53-dependent biological response to DNA damage. 
DISCUSSION
We have identified a natural p53 antisense transcript, Wrap53, that has a critical role in the posttranscriptional regulation of the p53 tumor suppressor gene. We show that Wrap53 has a major impact on basal p53 mRNA and protein levels by controlling p53 mRNA expression. The overlapping sequence (i.e., the 5 0 UTR) of p53 and Wrap53 is responsible for the regulation of p53 by Wrap53. The 5 0 UTR of p53 has previously been suggested to control its own RNA stability. A cis-acting element within this region was shown to be involved in rapid destabilization of p53 mRNA in immortal chicken and murine embryo fibroblasts (CEF/MEFs) (Kim et al., 2001b) .
Furthermore, we show that blocking of potential Wrap53 and p53 RNA interaction reduces basal levels of p53 and prevents induction of p53 after DNA damage. It is conceivable that Wrap53/p53 RNA interaction masks target sequences in p53 mRNA and, thus, protects it from degradation. If so, absence or removal of Wrap53 RNA, or otherwise disruption of this interaction, would expose p53 mRNA to putative regulatory factors, leading to its degradation and, hence, impaired p53 accumulation upon DNA damage.
Quantification of RNA levels revealed that p53 mRNA is expressed at 100-fold higher levels than the Wrap53a transcript. A number of other studies of sense-antisense pairs have indicated a similar discrepancy between the levels of the two transcripts and yet found that the antisense transcript regulates the sense transcript (Katayama et al., 2005; Fish et al., 2007; Oeder et al., 2007) . In fact, lower expression of the antisense transcript seems to be the rule. There is so far no convincing molecular explanation for how antisense transcripts might regulate their corresponding sense transcript at a posttranscriptional level. We speculate that a transient interaction between the complementary transcripts allows the antisense transcript to move on and target the next sense transcript in a ''hit and run'' fashion. It is possible that binding of the antisense transcript could result in some kind of permanent modification of the p53 mRNA that protects it from degradation even after detachment of the Wrap53 mRNA.
Transcription of Wrap53 gives rise to a perfectly matching complementary RNA with the capacity to hybridize and generate Wrap53/p53 RNA duplexes. Indeed, we found that the p53 sense and Wrap53a antisense transcripts are capable of forming duplex RNA when coexpressed in vitro. The formation of Wrap53/p53 RNA duplexes in living U2OS, MCF-7, and HCT116 cells was further investigated by RPA followed by either RT-PCR or northern blotting (10%-15% denaturing polyacrylamide gels) or by using biotinylated synthetic p53 target sense oligos to capture Wrap53 RNA. However, we were unable to detect endogenous Wrap53/p53 duplexes using these approaches (data not shown). The lack of sense/antisense duplex detection is consistent with several previous studies of sense/antisense transcripts. Although endogenous RNA duplexes have been reported in plants (Borsani et al., 2005) , such endogenous sense/ antisense duplexes have proved difficult to identify in human cells (Munroe and Zhu, 2006) . More than 40 cis-antisense RNAs have so far been identified and characterized, and in most cases, RNA duplexes have not been detected (Yu et al., 2008; Faghihi and Wahlestedt, 2006; Katayama et al., 2005; Munroe and Zhu, 2006) . This indicates that RNA duplexes in higher organisms are too transient and/or labile to allow detection by currently available methods. The transient nature of the RNA duplexes may be essential in order to avoid activation of the cellular interferon-mediated pathway that is triggered by the presence of viral RNA duplexes, resulting in shutdown of protein synthesis and culminating in apoptosis. It is also conceivable that the two mRNAs form secondary structures that interact in some other way than by classical duplex formation. Nonetheless, our finding that blocking of potential Wrap53/p53 RNA hybrids using 2-O-oligonucleotides reduces p53 expression provides solid indirect evidence to support the notion that Wrap53-mediated regulation of p53 occurs via Wrap53/p53 RNA interaction.
Interestingly, our comparative analysis revealed that p73 also is overlapped by a cis-antisense gene, Wrap73/WDR8, encoding a protein that belongs to the same family as Wrap53 (Koshizuka et al., 2001) . The conservation of the head-to-head organization of Wrap53 and p53, as well as Wrap73/WDR8 and p73, throughout evolution is striking. In fact, the overlapping region of Wrap53 and p53 shows higher conservation than many of the coding exons within the two genes, strongly indicating functional importance. Our data not only identify a mechanism for p53 and possibly also for p73 regulation but also highlight the role of antisense transcripts as regulatory RNAs in human cells. Growing evidence suggests that antisense transcription can have an important role in a range of human diseases (Lavorgna et al., 2004) . p53 is a key tumor suppressor that is mutated in around half of human tumors. Nonetheless, many tumors carry wild-type p53, and it is reasonable to assume that p53 function is impaired by other mechanisms in a large fraction of those tumors. Our discovery of Wrap53 as a regulator of p53 at the mRNA level raises the possibility that dysfunction of Wrap53 could contribute to tumorigenesis by failure to sustain p53 expression and function in wildtype p53-carrying tumors. Thus, the status of Wrap53 should be examined in further studies of primary tumor biopsies. In conclusion, it is clear that Wrap53 adds another level of complexity to the regulation of p53. Further studies of Wrap53 may provide a more complete understanding of the regulation of p53 in various physiological processes as well as during tumor development and may eventually also open avenues for therapeutic intervention in cancer.
EXPERIMENTAL PROCEDURES Computational Analysis and Cloning
Genomic DNA sequences were obtained from the human and mouse assemblies available through the UCSC genome browser home page (http://genome.ucsc. edu/) and analyzed using Blat search (http://genome-test.cse.ucsc.edu/cgi-bin/ hgBlat?command=start) and BLAST (http://www.ncbi.nlm.nih.gov/). Blast analysis was performed using Ensembl database version 37 (February, 2006) . To generate Wrap53 expression constructs, the full-length Wrap53a cDNA or deletion mutants were amplified by PCR (Advantage 2 polymerase, Clontech) and subcloned into pCMV-Tag2 vector (Invitrogen). All primers used for PCR amplifications are listed in Table S2 . The Wrap53a point mutant construct (CMVWrap53 aStop ) was made using the Site-directed Mutagenesis kit (Clontech) following the manufacturer's instructions. Sequence reactions were performed using the Cycle Sequencing Ready Reaction Kit (PE Applied Biosystems).
Cell Manipulations and Apoptosis Assays U2OS, MCF-7, MCF-7 p53wt/p53kd, and HCT116 cells were maintained in DMEM medium supplemented with 10% fetal bovine serum (Invitrogen). Human fibroblasts were maintained in F12/MEM medium. siRNA oligonucleotides targeting Wrap53 were designed using Ambion siRNA target finder (http://www.ambion.com/techlib/misc/siRNA_finder.html) and synthesized using Silencer siRNA Construction Kit (Ambion). All siRNA oligonucleotide sequences are listed in Table S2 . Cells were transfected with 140-500 ng siRNA/well in 6-well plates depending on cell line by using Oligofectamine Reagents (Invitrogen) following the manufacturer's instructions. Plasmid transfections were performed using Lipofectamine Reagent (Invitrogen). 2-O-methyl oligos (Thermo Electron Corporation) were transfected using Lipofectamine 2000 or the Oligofectamine Reagent (Invitrogen) at a 100-200 pmole/ml concentration (see Table S2 ).
Changes in DJm were detected by incubation of living cells with tetramethylrhodamine ethyl ester (TMRE) (Invitrogen, Carlsbad, CA) and analyzed by a FACS calibur flow cytometer (Becton Dickinson) using the Cell Quest software. In parallel, redistribution of plasma membrane phosphatidyl serine (PS) was assessed using Annexin V FLUOS (Boehringer Mannheim, Mannheim) according to the manufacturer's protocol.
Western Blotting and Antibodies
To prepare protein lysates, cells were harvested, washed, and lysed in ice cold 13 sample buffer (100 mM Tris-HCL [pH 8], 150 mM NaCl, 1% NP-40, 1% PMSF, and 1% protease inhibitor cocktail).
Western blotting was performed according to standard protocols. To analyze Wrap53 protein levels, we generated a Wrap53 polyclonal antiserum which was affinity-purified. Rabbits were immunized with a KLH-conjugated Wrap53 peptide (NH2-) CRVFPEPTESGDEGE (-CONH2), corresponding to amino acids 483-496 of full-length Wrap53 protein, followed by affinity IgG purification (Innovagen AB, Sweden). This antiserum specifically detects Flag-tagged and endogenous Wrap53 protein with an apparent molecular weight of 75 kD as assessed by western blot analysis of cells overexpressing full-length Wrap53 protein (data not shown) and U2OS whole cell lysate ( Figure S14 ). p53-specific monoclonal antibody (DO-1, Pharmigen), p21-specific monoclonal antibody (554228, Pharmigen), and PUMA-specific polyclonal antibody (ab9643-100, Abcam) were used for endogenous protein detection. As loading control, anti-b-actin monoclonal antibody (Sigma) was used. Cell fractionation on protein level was performed using Nuclear Extract Kit (Active Motif) following the manufacturer's instructions.
RNA Preparations, Northern Blotting, RQ-RT-PCR, and QuantiGene Total RNA was extracted using the Trizol reagent (Invitrogen) from tumor cell lines. Cytoplasmic RNA was purified using the RNeasy Mini Kit (QIAGEN). Nuclear RNA was purified by Trizol reagent from the nuclear pellet remaining after the first centrifugation in the above described protocol.
Twelve micrograms of total RNA was separated on a 1% formaldehyde-MOPS agarose gel and blotted into Z-probe nylon membrane (Bio-Rad Laboratories, Inc). Total RNA and mRNA (MTN blots, Clontech) were hybridized with PCR derived probes from Wrap53, p53, p73, GAPDH and b-Actin. Hybridization was carried out at 42 C using Ultrahyb solution (Ambion) and labeling and purification of probes were performed using Ready-to-go beads and ProbeQuant G-50 Micro Columns (Amersham Bioscience). The RNA was reverse-transcribed with First Strand cDNA Synthesis Kit using Superscript II (Invitrogen), and RT-PCR was performed using Titanium polymerase (Clontech). Quantitative real-time PCR was carried out in the Applied Biosystems 7500 real-time PCR using transcript-specific TaqMan Gene Expression Assays (Applied Biosystems) (see Table S2 ). Quantification of RNA levels was also performed using QuantiGene that quantifies RNA directly from crude cell lysates without any RNA purification, reverse transcription, or target amplification. The assay was performed according to the manufacturer's recommendations (Panomics) (Canales et al., 2006) .
Luciferase Assays
For the p53 promoter studies, two luciferase constructs were used. The sensor construct containing the human p53 promoter starting from P1 and including 1 kb upstream sequences was cloned in immediately upstream of firefly luciferase gene in the pGL3 Basic vector (Promega). In the control construct the pCMV promoter was instead cloned upstream of the luciferase gene.
The constructs shown in Figure 4 represent two sensor constructs containing sequences of different length of the first exon of human p53 cloned immediately upstream of the luciferase gene in the pGL3-Promoter vector (Promega). The control construct only contains the SV40 promoter in front of the luciferase gene. Primers used for cloning are listed in Table S2 .
For the knockdown experiments, 20,000 cells/well were plated in 24-well plates 1 day prior to transfection. Cells were transfected with 125 ng siRNA/ well using Oligofectamine. Thirty hours post-siRNA transfection, cells were retransfected with 200-400 ng of firefly luciferase plasmid/well and 10-20 ng Renilla luciferase plasmid/well using Lipofectamine 2000 and grown for another 18 hr. Cells were harvested in the lysis buffer (Promega), and luciferase activity was measured using the Dual Luciferase Assay Kit (Promega). For Wrap53 overexpression experiments, 80,000 cells/well were plated. The following day, 100 ng of firefly lucifease, 20 ng of Renilla, and 600 ng of either of the plasmids CMV-empty, CMV-Wrap53-E1aS/L, or CMV-Wrap53-E1b, were transfected using Lipofectamine 2000. Cells were harvested in the lysis buffer, and luciferase activity was measured using the Dual Luciferase Assay Kit. Firefly luciferase activity was normalized to Renilla luciferase activity for each transfected well. Each transfected sample was assayed in triplicate or duplicate.
In Vitro Trancription/Translation and RNase Protection Assay
In vitro transcription and translation was performed using the TNT Quick Coupled Transcription/Translation System (Promega) according to the manufacturer's instructions. RNase protection assay was carried out by first dividing the purified RNA into three parts: sample of interest, positive, and negative control. The negative control was first heat-denatured at 94 C for 15 min.
Next, all three samples were treated with DNase I (Invitrogen) in DNase I buffer. In addition, RNase A was added to the sample of interest, and the negative control and RNaseOut (Invitrogen) was added to the positive control. After 30 min to 1 hr of treatment, the RNA from all three samples was purified using Trizol reagent. Duplex formation was then analyzed by RT-PCR using primers within the overlapping region, as previously described.
ACCESSION NUMBERS
Genetic accession numbers were deposited into GenBank as follows: BM009851 (Wrap53a EST), U58658 (Wrap53g EST), NM_018081 (Wrap53b EST), AY766322 (cloned and edited Wrap53a1), DQ431240 (cloned and edited Wrap53b1), DQ431241 (cloned and edited Wrap53g1), AAH02336 (Wrap53 protein), NM_011640 (mouse p53 EST), BC069868 (mouse Wrap53 EST), and BX331531 (Wrap73).
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